The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. (Q34209536)
Jump to navigation
Jump to search
scientific article
Language | Label | Description | Also known as |
---|---|---|---|
English | The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. |
scientific article |
Statements
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial (English)
John R Teerlink
Roxy Senior
Barry H Greenberg
Fady I Malik
Scott M Wasserman
Evgeny M Nifontov
Vitaly A Tsyrlin
Jamil Mayet
Darrel P Francis
Tamaz Shaburishvili
Mark Monaghan
Mitchell Saltzberg
Jacqueline H Lee
Khalil G Saikali
Cyril P Clarke
Jonathan H Goldman
Andrew A Wolff